Psychopharmacology

The study sheds light on the potential risks and adverse effects of polypharmacy in patients with complex psychiatric conditions.

Here’s how an integrated psychosocial and pharmacologic approach can enhance SUD treatment.

Here are highlights from the last day of this year’s APA Annual Meeting.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

The extension trial aims to address the cognitive impairment often observed in schizophrenia.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

Joseph F. Goldberg, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

This 2024 APA Annual Meeting poster covered a literature review on the relationship between stimulant use and failure to thrive in pediatric patients with ADHD.

Explore treatment resistance at the 2024 APA Annual Meeting!

Here are some updates from the world of psychiatry throughout the month of April.

Here are highlights from the week in Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of March.

“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.